| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Eli Lilly & Co. (LSE: 0Q1G)
0Q1G Technical Analysis
5
| As on 4th Feb 2022 0Q1G STOCK Price closed @ 244.96 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 40.96 & Strong Buy for SHORT-TERM with Stoploss of 173.51 we also expect STOCK to react on Following IMPORTANT LEVELS. |
0Q1GSTOCK Price
| Open | 244.96 | Change | Price | % |
| High | 244.96 | 1 Day | 19.65 | 8.72 |
| Low | 244.96 | 1 Week | 9.71 | 4.13 |
| Close | 244.96 | 1 Month | 41.28 | 20.27 |
| Volume | 435 | 1 Year | 76.54 | 45.45 |
| 52 Week High 249.05 | 52 Week Low 166.33 | ||||
LSE UK Most Active Stocks
| DKE | 0.15 | 0.00% |
| NNN | 0.09 | 50.00% |
| SYME | 0.10 | -9.09% |
| DMTR | 0.03 | 0.00% |
| PREM | 0.53 | 3.92% |
| MCLS | 1.68 | 46.09% |
| YGEN | 0.49 | 0.00% |
| CLON | 0.11 | 0.00% |
| VOD | 71.04 | 0.57% |
| BOIL | 0.10 | 0.00% |
LSE UK Top Gainers Stocks
LSE UK Top Losers Stocks
| 0Q1G Daily Charts |
0Q1G Intraday Charts |
Whats New @ Bazaartrend |
0Q1G Free Analysis |
|
|
0Q1G Important Levels Intraday
| RESISTANCE | 244.96 |
| RESISTANCE | 244.96 |
| RESISTANCE | 244.96 |
| RESISTANCE | 244.96 |
| RESISTANCE | 244.96 |
| RESISTANCE | 244.96 |
| RESISTANCE | 244.96 |
| RESISTANCE | 244.96 |
0Q1G Forecast May 2024
| 4th UP Forecast | 337.55 |
| 3rd UP Forecast | 307.86 |
| 2nd UP Forecast | 289.5 |
| 1st UP Forecast | 271.15 |
| 1st DOWN Forecast | 218.77 |
| 2nd DOWN Forecast | 200.42 |
| 3rd DOWN Forecast | 182.06 |
| 4th DOWN Forecast | 152.37 |
0Q1G Weekly Forecast
| 4th UP Forecast | 270.51 |
| 3rd UP Forecast | 262.32 |
| 2nd UP Forecast | 257.25 |
| 1st UP Forecast | 252.19 |
| 1st DOWN Forecast | 237.73 |
| 2nd DOWN Forecast | 232.67 |
| 3rd DOWN Forecast | 227.60 |
| 4th DOWN Forecast | 219.41 |
0Q1G Forecast2024
| 4th UP Forecast | 404.36 |
| 3rd UP Forecast | 353.24 |
| 2nd UP Forecast | 321.64 |
| 1st UP Forecast | 290.04 |
| 1st DOWN Forecast | 199.88 |
| 2nd DOWN Forecast | 168.28 |
| 3rd DOWN Forecast | 136.68 |
| 4th DOWN Forecast | 85.56 |
Eli Lilly & Co. ( LSE UK Symbol : 0Q1G )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
0Q1G Business Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; MiNA Therapeutics Limited; Verge Genomics; and The Banner Alzheimer's Institute, as well as Kumquat Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. Address: Lilly Corporate Center, Indianapolis, IN, United States, 46285
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service